Innate Pharma (IPHA) Other Non-Current Assets (2017 - 2025)

Innate Pharma (IPHA) has 9 years of Other Non-Current Assets data on file, last reported at $1.1 million in Q4 2025.

• For the quarter ending Q4 2025, Other Non-Current Assets rose 79.41% year-over-year to $1.1 million; the trailing twelve-month figure through Dec 2025 stood at $1.1 million (up 79.41% YoY), and the FY2025 full-year result was $1.1 million, up 79.41% from the prior year.
• Other Non-Current Assets for Q4 2025 stood at $1.1 million, up from $653140.7 in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $1.1 million in Q4 2025 and bottomed at $91535.4 in Q2 2024.
• The 5-year median for Other Non-Current Assets is $164149.6 (2021), against an average of $338193.5.
• The widest annual swing landed in 2021, when Other Non-Current Assets slumped 99.82%; it then jumped 613.54% in 2025.
• A 5-year view of Other Non-Current Assets shows it stood at $169307.7 in 2021, then dropped by 10.21% to $152016.9 in 2022, then tumbled by 38.42% to $93606.8 in 2023, then soared by 556.41% to $614442.4 in 2024, then surged by 79.41% to $1.1 million in 2025.
• The last three Other Non-Current Assets figures came in at $1.1 million (Q4 2025), $653140.7 (Q2 2025), and $614442.4 (Q4 2024), per Business Quant data.

Peer Comparison